Prothena Q2 2026: Net Loss Narrows to $18.6M as Restructuring Winds Down; Cash at $288M
PRTA sits 18% above its 52-week low of $7.28.
Summary
Prothena reported a Q2 2026 net loss of $18.6 million, a sharp improvement from the $125.8 million loss a year ago, as R&D spending plummeted following the wind-down of internal programs. Cash stands at $288.2 million, and the restructuring is essentially complete.
Key Events · Earnings and Guidance · PRTA
-
Q2 Loss Narrows Sharply
Driven by a 78% drop in R&D expenses to $8.8 million as the birtamimab and PRX012 programs wind down, the net loss narrowed to $18.6 million in Q2 2026 from $125.8 million in Q2 2025.
-
Six-Month Profit on Milestone
For the first half of 2026, net income reached $14.1 million, boosted by a $50 million development milestone from Novo Nordisk for coramitug's Phase 3 trial.
-
Cash Position and Buybacks
Cash and equivalents totaled $288.2 million at June 30, 2026, down from $307.5 million at year-end 2025, partly due to $22.3 million spent on share repurchases under the $100 million buyback plan.
-
Restructuring Nearly Complete
With the program winding down, the restructuring liability fell to $0.3 million; cumulative costs incurred are $28.3 million out of the $32.6 million expected.
Analysis · PRTA · Life Sciences
A dramatically improved bottom line highlights Prothena's second-quarter results, with the net loss shrinking to $18.6 million from $125.8 million a year ago. The turnaround reflects a sharp reduction in R&D spending after the discontinuation of birtamimab and the wind-down of PRX012, along with a $50 million milestone payment from Novo Nordisk recognized earlier in the year. Operating expenses fell 75% year-over-year, and the restructuring program is nearly complete, leaving only $0.3 million in remaining liabilities. The company ended the quarter with $288.2 million in cash, down modestly from year-end after $22.3 million in share repurchases. While the pipeline is now heavily reliant on partnered programs, the leaner cost structure and cash runway provide stability as partnered assets advance through late-stage trials.
At the time of this filing, PRTA was trading at $8.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $449.2M. The 52-week trading range was $7.28 to $11.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.